We are thrilled to announce a successful pre-IND meeting with the FDA for EXL01, our novel oral macrophage-targeting immunomodulator. The positive outcome of this meeting is a testament to the comprehensive data we have compiled over the years, spanning preclinical studies, Manufacturing and Control strategies, and phase-1 clinical study.This milestone constitutes a solid foundation in the US to expand from.